Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Preferred Dividend Payments (2018 - 2025)

Historic Preferred Dividend Payments for Ernexa Therapeutics (ERNA) over the last 7 years, with Q2 2025 value amounting to $8000.0.

  • Ernexa Therapeutics' Preferred Dividend Payments changed 0.0% to $8000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $16000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $16000.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Ernexa Therapeutics reported Preferred Dividend Payments of $8000.0 as of Q2 2025, which was down 0.0% from $8000.0 recorded in Q4 2024.
  • Over the past 5 years, Ernexa Therapeutics' Preferred Dividend Payments peaked at $8000.0 during Q2 2022, and registered a low of $8000.0 during Q2 2022.
  • In the last 4 years, Ernexa Therapeutics' Preferred Dividend Payments had a median value of $8000.0 in 2022 and averaged $8000.0.
  • The largest annual percentage gain for Ernexa Therapeutics' Preferred Dividend Payments in the last 5 years was 0.0% (2023), contrasted with its biggest fall of 0.0% (2023).
  • Ernexa Therapeutics' Preferred Dividend Payments (Quarter) stood at $8000.0 in 2022, then changed by 0.0% to $8000.0 in 2023, then changed by 0.0% to $8000.0 in 2024, then changed by 0.0% to $8000.0 in 2025.
  • Its last three reported values are $8000.0 in Q2 2025, $8000.0 for Q4 2024, and $8000.0 during Q2 2024.